Literature DB >> 2498664

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

V K Chaudhary1, C Queen, R P Junghans, T A Waldmann, D J FitzGerald, I Pastan.   

Abstract

Antibodies and growth factors have been chemically coupled to different toxins to produce cytotoxic molecules that selectively kill cells bearing appropriate antigens or receptors. Antibody-toxin conjugates (immunotoxins) produced using conventional chemical coupling techniques have several undesirable characteristics. The smallest binding unit of an antibody is an Fv fragment which consists of a light and heavy chain variable domain. Recently, active single chain Fv fragments of antibodies have been produced in Escherichia coli by attaching the light and heavy chain variable domains together with a peptide linker. Here we describe the construction and expression in E. coli of a single chain antibody toxin fusion protein, anti-Tac(Fv)-PE40, in which the variable regions of anti-Tac, a monoclonal antibody to the p55 subunit of the human interleukin-2 receptor, are joined in peptide linkage to PE40, a modified form of Pseudomonas exotoxin lacking its binding domain. Anti-Tac(Fv)-PE40 was very cytotoxic to two interleukin-2 receptor-bearing human cell lines but was not cytotoxic to receptor-negative cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498664     DOI: 10.1038/339394a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  72 in total

1.  Regulated secretion and purification of recombinant antibodies in E. coli.

Authors:  S Dübel; F Breitling; I Klewinghaus; M Little
Journal:  Cell Biophys       Date:  1992 Aug-Dec

Review 2.  Recombinant human monoclonal antibodies. Basic principles of the immune system transferred to E. coli.

Authors:  P Fuchs; S Dübel; F Breitling; M Braunagel; I Klewinghaus; M Little
Journal:  Cell Biophys       Date:  1992 Aug-Dec

Review 3.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

4.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 6.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

7.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 8.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 9.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 10.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.